Filing Details
- Accession Number:
- 0001567619-19-020466
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-11-05 18:05:29
- Reporting Period:
- 2019-11-04
- Accepted Time:
- 2019-11-05 18:05:29
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 874716 | Idexx Laboratories Inc | IDXX | In Vitro & In Vivo Diagnostic Substances (2835) | 010393723 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1094176 | Anne M Szostak | One Idexx Drive Westbrook ME 04092 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2019-11-04 | 2,300 | $279.10 | 3,899 | No | 4 | S | Indirect | M. Anne Szostak Trust |
| Common Stock | Disposition | 2019-11-04 | 983 | $279.99 | 2,916 | No | 4 | S | Indirect | M. Anne Szostak Trust |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Indirect | M. Anne Szostak Trust |
| No | 4 | S | Indirect | M. Anne Szostak Trust |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 6,717 | Indirect | 2018 Szostak IDEXX GRAT |
| Common Stock | 584 | Direct |
Footnotes
- Represents the weighted average price of the shares sold ranging from a low of $278.56 to a high of $279.51 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- Represents the weighted average price of the shares sold ranging from a low of $279.58 to a high of $280.48 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
Billionaire Hedge Funds
